“Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)”. SKIN The Journal of Cutaneous Medicine, vol. 3, Nov. 2019, p. S39, https://doi.org/10.25251/skin.3.supp.39.